AI Summary
The 25th International AIDS Conference highlighted the results of the PURPOSE 1 trial of lenacapavir injections for HIV prevention. The 6-monthly injections were found to be 100% effective in preventing HIV, surpassing daily oral PrEP with tenofovir-based drugs. This novel approach could be a game-changer for PrEP if access is adequate.
The 25th International AIDS Conference, held July 22–26 in Munich, Germany, was dominated by one topic: the results of the PURPOSE 1 trial of lenacapavir 6-monthly injections for the prevention of HIV. The novel approach to pre-exposure prophylaxis (PrEP) had remarkable results. Compared with the expected background HIV incidence, and in comparison to daily oral prevention with tenofovir-based drugs, lenacapavir given every 6 months was 100% effective in preventing HIV. There were no infections at all in 2134 participants.